ePrints

PARP inhibitors and cancer therapy - early results and potential applications

Lookup NU author(s): Dr Christopher Jones, Professor Ruth Plummer

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Polyadenosine diphosphate-ribose polymerase (PARP) inhibitors are emerging as an exciting new class of agents for treating cancer. There is pre-clinical evidence for their use to potentiate both chemotherapeutic agents and radiotherapy, and also as single agents. This paper discusses the early clinical work published showing their use in combination with temozolomide in malignant melanoma, and in familial (BRCA-related) cancers.

Publication metadata

Author(s): Jones C, Plummer ER

Publication type: Article

Publication status: Published

Journal: British Journal of Radiology

Year: 2008

Volume: 81

Issue: Supplement 1

Pages: S2-S5

ISSN (print): 0007-1285

ISSN (electronic): 1748-880X

Publisher: British Institute of Radiology

URL: http://dx.doi.org/10.1259/bjr/30872348

DOI: 10.1259/bjr/30872348

Altmetrics

Share